View Older Stories View More Recent Stories

May 27, 2020 06:45AM Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
May 27, 2020 06:45AM Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
May 26, 2020 06:52AM Zynerba Pharma (ZYNE) Presents Phase 2 BELIEVE Safety, Efficacy & Quality of Life Data in Developmental and Epileptic Encephalopathies at 2020 AAN Virtual Meetings
May 26, 2020 06:52AM Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtu
May 26, 2020 06:50AM Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurol
May 22, 2020 07:30AM Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 21, 2020 08:00AM Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic
May 11, 2020 06:50AM Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
May 11, 2020 06:50AM Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
Apr 10, 2020 08:00AM Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference
Mar 10, 2020 06:50AM Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
Mar 10, 2020 06:50AM Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
Mar 9, 2020 08:30AM Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting
Mar 5, 2020 08:30AM Zynerba Pharmaceuticals to Present at the 32nd Annual ROTH Conference
Mar 3, 2020 12:08PM Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population
Mar 3, 2020 12:07PM Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers 
Mar 3, 2020 12:07PM Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers 
Mar 3, 2020 12:07PM Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population
Feb 26, 2020 06:58AM Zynerba Pharma (ZYNE) Reports Complete Enrollment in Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome
Feb 26, 2020 06:50AM Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome
Feb 26, 2020 06:50AM Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome
Feb 25, 2020 07:16AM Zynerba Pharma (ZYNE) Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol
Feb 25, 2020 07:15AM Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol
Feb 20, 2020 08:30AM Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual Meeting
Feb 3, 2020 06:47AM Zynerba Pharma (ZYNE) Achieves Patient Screening Target for Pivotal Trial of Zygel in Fragile X Syndrome
Feb 3, 2020 06:45AM Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome
Feb 3, 2020 06:45AM Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome
Feb 3, 2020 06:45AM Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome
Jan 13, 2020 06:50AM Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome
Jan 13, 2020 06:47AM Zynerba Pharma (ZYNE) Achieves Target Enrollment in Phase 2 Trial of Zygel in Autism Spectrum Disorder
Jan 13, 2020 06:45AM Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder
Jan 13, 2020 06:45AM Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder
Nov 12, 2019 07:09AM Zynerba Pharma (ZYNE) Granted New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol
Nov 12, 2019 07:00AM Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol
Nov 6, 2019 06:45AM Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
Nov 6, 2019 06:45AM Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
Oct 25, 2019 01:45PM Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
Sep 26, 2019 11:50AM Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Sep 18, 2019 06:32AM Zynerba Pharma (ZYNE) Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel in DEE
Sep 18, 2019 06:30AM Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)
Sep 18, 2019 06:30AM Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)
Sep 5, 2019 07:00AM New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)
Sep 5, 2019 07:00AM Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms
Sep 5, 2019 07:00AM New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)
Sep 5, 2019 07:00AM Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms
Sep 3, 2019 11:30AM Zynerba Pharmaceuticals to Present at Two Upcoming Conferences
Aug 29, 2019 07:30AM Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium
Aug 6, 2019 08:00AM Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders
Aug 6, 2019 06:45AM Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
Aug 6, 2019 06:45AM Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
View More Recent Stories View Older Stories